Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: US FDA Receives Submissions Galore As Year Ends

Executive Summary

A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.
Advertisement

Related Content

Buoyed By Phase III Rosacea Success, Foamix Plans Commercial Transition
Keeping Track: FDA Starts November With A Bang
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
Foamix's Minocycline Foam: A Game Changer In Severe Acne?
Rheumatoid Arthritis Data Position Filgotinib Ahead Of Competition, But It's Playing Catch-Up
Spectrum Gears Up To File Rolontis, Stresses Patient Access
AbbVie Soothes Safety Fears With More Upadacitinib RA Data
Nabriva On Pace For Lefamulin NDA; Stock Tumbles Despite Trial Success
Refining A Controversial Endpoint: Sarepta Banking On Dystrophin Levels For Golodirsen Approval In DMD
Pharmaxis Faces New Study Requirement For CF Drug Bronchitol

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124502

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel